C. McKeever

Low-Radiation-Dose Modified Small Bowel CT for Evaluation of Recurrent Crohn's Disease

A. Kielar, R. El-Maraghi, H. Tao, 2011, Gastroenterology research and practice.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

H K Genant, Jacques P. Brown, H. Genant, 1999, JAMA.

Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis

S. Greenspan, A. Mulloy, S. Weiss, 2002, Annals of Internal Medicine.

Fracture risk remains reduced one year after discontinuation of risedronate

N. Watts, A. Grauer, A. Chines, 2008, Osteoporosis International.

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.

R. Recker, S. Greenspan, A. Mulloy, 2000, The Journal of clinical endocrinology and metabolism.

An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.

M. Greenwald, C. McKeever, N. Gupta, 2000, Clinical therapeutics.

Regional migratory osteoporosis.

R. Steiner, C. McKeever, 1973, Journal of the Canadian Association of Radiologists.

Differential Effects of Alendronate and Estrogen on the Rate of Bone Loss After Discontinuation of Treatment: P-80.

S. Greenspan, A. Mulloy, S. Weiss, 1999 .